CPhI Online

- Biopharma News

Codexis and Takeda collaborate to advance novel gene therapies

23 Mar 2020

Codexis' CodeEvolver protein engineering technology. Source: Codexis Inc.

Partnership to leverage Codexis’ protein engineering platform for the discovery and development of novel transgenes for lysosomal storage disorders and blood factor deficiencies.

Codexis, a protein engineering company and developer of novel biotherapeutics, has signed a strategic collaboration and license agreement with Takeda Pharmaceutical Company for the research and development of novel gene therapies for certain disease indications, including the treatment of lysosomal storage disorders and blood factor deficiencies.

Codexis will generate novel gene sequences encoding protein variants tailored to enhance efficacy as a result of increased activity, stability, and cellular uptake using its CodeEvolver protein engineering platform.

Takeda will combine these improved transgenes with its gene therapy capabilities to generate novel candidates for the treatment of rare genetic disorders.

“The prospects of these improved sequences for the development of differentiated gene therapies for patients with rare disease,s therefore, holds great promise,” stated John Nicols, Codexis’ President and CEO.

The parties will begin collaborative work on three initial programs. Codexis is responsible for the creation of novel enzyme sequences for advancement as gene therapies into pre-clinical development. Takeda is responsible for the pre-clinical and clinical development and commercialization of gene therapy products resulting from the collaboration programs.

In addition to the three initial programs, Takeda may initiate up to four additional programs for separate target indications.

Subject to the terms of the agreement, Codexis is eligible to receive an upfront payment, reimbursement for research and development fees, development and commercial milestone payments, and low- to mid-single-digit percentage royalties on sales of any commercial product developed through such initial programs and any other programs that Takeda may elect under the agreement.

Gjalt Huisman, Codexis’ Senior Vice-President, and General Manager, Novel Biotherapeutics said: “We are looking forward to working with Takeda to advance our pre-clinical assets for lysosomal storage disorders, and to broaden our biotherapeutics pipeline to now include blood factor disorders.”

Read More

Related Content